

Attorney Docket No.: **DEX0489US.NP**
Inventors: **Duan et al.**
Serial No.: **10/558,543**
Filing Date: **October 23, 2006**
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1-19 (canceled)

Claim 20 (currently amended): A kit comprising a suitable assay for measuring Cln101 levels and a suitable assay for measuring CA125 levels, wherein the assay for Cln101 comprises an antibody of claim 30.

Claim 21-23 (canceled)

Claim 24 (previously presented): The antibody of claim 30 which binds to mammalian Cln101 in vivo or in vitro.

Claim 25 (previously presented): The antibody of claim 30 which internalizes upon binding to Cln101 on a mammalian cell in vivo.

Claim 26 (currently amended): The antibody of claim 30 which is ~~a monoclonal antibody~~, an antibody fragment or a chimeric or a humanized antibody.

Claims 27-28 (canceled)

Claim 29 (original): The antibody of claim 26 which is produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-5877 and PTA-5876.

Attorney Docket No.: **DEX0489US.NP**
Inventors: **Duan et al.**
Serial No.: **10/558,543**
Filing Date: **October 23, 2006**
Page 4

Claim 30 (currently amended): An isolated monoclonal antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5877 and PTA-5876.

Claim 31 (previously presented): The antibody of claim 30 which is conjugated to a growth inhibitory agent or a cytotoxic agent.

Claim 32-44 (canceled)

Claim 45 (previously presented): An isolated cell that produces the antibody of claim 26.

Claim 46 (original): The cell of claim 45, wherein the cell is selected from the group consisting of hybridoma cells deposited under American Type Culture Collection accession number PTA-5877 and PTA-5876.

Claim 47 (canceled)

Claim 48 (previously presented): A composition comprising the antibody of claim 30, and a carrier.

Claim 49-50 (canceled)

Claim 51 (original): The composition of claim 48, wherein the antibody is a human or humanized antibody and the carrier is a pharmaceutical carrier.

Attorney Docket No.: DEX0489US.NP
Inventors: Duan et al.
Serial No.: 10/558,543
Filing Date: October 23, 2006
Page 5

Claim 52-94 (canceled)

Claim 95 (currently amended): A kit comprising a suitable assay for measuring Cln101 levels and a suitable assay for measuring Prostate Specific Antigen (PSA) levels wherein the assay for Cln101 comprises ~~the antibodies~~ an antibody of claim 30.

Claim 96 (previously presented): The antibody of claim 30 which is detectably labeled.

Claim 97 (previously presented): The antibody of claim 96 wherein the label is selected from the group comprising radioisotope, fluorescent, enzymatic, biotin, and gold particle labels.

Claim 98 (new): The antibody of claim 26 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5877.

Claim 99 (new): The antibody of claim 26 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5876.

Claim 100 (new): The cell of claim 45, wherein the cell is a hybridoma cell deposited under American Type Culture Collection accession number PTA-5877.

Attorney Docket No.: **DEX0489US.NP**
Inventors: **Duan et al.**
Serial No.: **10/558,543**
Filing Date: **October 23, 2006**
Page 6

Claim 101 (new): The cell of claim 45, wherein the cell is a
hybridoma cell deposited under American Type Culture
Collection accession number PTA-5876.